金色化物RK1通过FSP1-依赖途径诱导肝细胞癌细胞中的铁亡
Yulang Jiang1,2,3, Yongxin Yu1,2,3, Ziyang Pan1,2,3
1Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
概括
银化物RK1有效诱导肝细胞癌 (HCC) 细胞中的铁亡,细胞死亡途径. 这通过一种依赖于铁灭抑制蛋白1 (FSP1) 的机制发生,为HCC提供了潜在的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因.
- 铁亡是一种受调节的细胞死亡途径,在HCC治疗中是一个有前途的治疗标.
- 人参化物RK1正在研究其在HCC中诱导铁亡的潜力.
研究的目的:
- 为了研究金氏化物RK1对HCC细胞中铁亡诱导的影响.
- 为了阐明基因化物RK1诱导的铁亡的潜在分子机制.
- 评估铁灭抑制蛋白1 (FSP1) 在这个过程中的作用.
主要方法:
- 利用了HepG2 HCC细胞系,并评估了生存能力,细胞毒性和殖民地形成.
- 使用亡,亡和铁亡的抑制剂来确定细胞死亡机制.
- 量化了谷氨 (GSH),甲 (MDA) 和铁离子的细胞内水平.
- 评估了与ferroptosis相关的基因的蛋白质表达和调节的FSP1表达.
主要成果:
- 银化物RK1以剂量依赖的方式 (IC50 ≈ 20μM) 抑制了HCC细胞活力和殖民地形成.
- RK1治疗降低了细胞内GSH,增加了MDA和铁离子水平,表明铁亡.
- 由金氏化物RK1诱导的细胞死亡被铁死抑制剂特别逆转.
- 调节FSP1表达 (过度表达或沉默) 显著影响了RK1诱导铁亡的能力.
结论:
- 金色化物RK1在肝细胞癌细胞中促进铁化.
- 兴生素RK1诱导的铁亡的机制依赖于铁亡抑制蛋白1 (FSP1).
- 这项研究突出了一个潜在的FSP1-依赖的治疗策略,用于使用人参化物RK1.1,治疗HCC.
更多相关视频
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
342
09:02Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing
Published on: June 9, 2017
23.2K
相关概念视频
01:16Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K